GENEVA, July 27 -- QILU PHARMACEUTICAL CO., LTD. filed a patent application (CN2026/072666) for “PHARMACEUTICAL COMPOSITION COMPRISING ANTI-CTLA4 AND ANTI-PD1 ANTIBODIES, AND THERAPEUTIC USE THEREOF”. With publication no. WO/2026/153394, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 39/395
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....